Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Jan;15(1):506.
doi: 10.1007/s11910-014-0506-0.

Radiogenomics and imaging phenotypes in glioblastoma: novel observations and correlation with molecular characteristics

Affiliations
Free article
Review

Radiogenomics and imaging phenotypes in glioblastoma: novel observations and correlation with molecular characteristics

Benjamin M Ellingson. Curr Neurol Neurosci Rep. 2015 Jan.
Free article

Abstract

Radiogenomics is a provocative new area of research based on decades of previous work examining the association between radiological and histological features. Many generalized associations have been established linking anatomical imaging traits with underlying histopathology, including associations between contrast-enhancing tumor and vascular and tumor cell proliferation, hypointensity on pre-contrast T1-weighted images and necrotic tissue, and associations between hyperintensity on T2-weighted images and edema or nonenhancing tumor. Additionally, tumor location, tumor size, composition, and descriptive features tend to show significant associations with molecular and genomic factors, likely related to the cell of origin and growth characteristics. Additionally, physiologic MRI techniques also show interesting correlations with underlying histology and genomic programs, including associations with gene expression signatures and histological subtypes. Future studies extending beyond simple radiology-histology associations are warranted in order to establish radiogenomic analyses as tools for prospectively identifying patient subtypes that may benefit from specific therapies.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Lancet Oncol. 2009 May;10 (5):459-66 - PubMed
    1. Surg Neurol. 2009 Sep;72(3):242-6; discussion 246-7 - PubMed
    1. Radiology. 2013 May;267(2):560-9 - PubMed
    1. Neuroimage. 2012 Jan 16;59(2):908-16 - PubMed
    1. Nat Biotechnol. 2008 Jan;26(1):101-6 - PubMed